{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:16:39Z","timestamp":1793873799575,"version":"4.6.1"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Incarcerated populations experience an elevated prevalence of opioid use disorder (OUD). Federal correctional institutions in Canada have increasingly treated OUD among correctional populations via opioid agonist treatment (OAT) \u2013 an evidence based pharmacotherapy that works to reduce drug use and related health harms. However, there is limited evidence regarding incarcerated individuals\u2019 experiences with institutional-based OAT, as well potential OAT-related community release prospects. This information is important for optimal treatment retention and improved health. To address this knowledge gap, we conducted a longitudinal follow-up study examining OAT-related experiences among federally incarcerated individuals before and after community release. This article focuses on the baseline (pre-release) data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This mixed-methods study examined OAT-related experiences and release prospects among <jats:italic>n<\/jats:italic>\u2009=\u200946 individuals scheduled for community release, recruited from seven federal prisons located in Ontario, Canada. Participants underwent a comprehensive interviewer-administered on-site assessment, including quantitative and qualitative items. Assessment data was furthermore linked to administrative correctional data. Data were analyzed using thematic qualitative and descriptive quantitative approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants had complex histories with opioid use including related negative health outcomes. Experiences with institutional OAT were divergent and provision was not standardized; those with OAT engagement pre-admission did not experience many challenges, whereas those initiating OAT during incarceration experienced barriers such as treatment waitlists and adverse process experiences. Most participants expressed a preference for buprenorphine-naloxone over methadone, but described difficulties accessing it. Participants were keen to transition into community-based treatment, yet envisaged prospective barriers and facilitators concerning successful reintegration and treatment continuity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Major barriers towards the current administration of OAT in federal correctional systems in Canada exist, including extensive waitlists, non-standardized practices, and challenges accessing preferred OAT formulations; this contributes to sub-optimal treatment. Eliminating waitlists, standardizing OAT provision, providing additional OAT options, and more comprehensive release planning may be essential for treatment retention and positive outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-12685-0","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T16:03:28Z","timestamp":1646409808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study"],"prefix":"10.1186","volume":"22","author":[{"given":"Cayley","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frishta","family":"Nafeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna Farrell","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Derkzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"10","key":"12685_CR1","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/add.13877","volume":"112","author":"S Fazel","year":"2017","unstructured":"Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725\u201339. https:\/\/doi.org\/10.1111\/add.13877.","journal-title":"Addiction"},{"issue":"13","key":"12685_CR2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMp1900069","volume":"380","author":"IA Binswanger","year":"2019","unstructured":"Binswanger IA. Opioid use disorder and incarceration: hope for ensuring the continuity of treatment. N Engl J Med. 2019;380(13):1193.","journal-title":"N Engl J Med"},{"issue":"1","key":"12685_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13722-019-0138-4","volume":"14","author":"J Tsai","year":"2019","unstructured":"Tsai J, Gu X. Utilization of addiction treatment among US adults with history of incarceration and substance use disorders. Addict Sci Clin Pract. 2019;14(1):9.","journal-title":"Addict Sci Clin Pract"},{"key":"12685_CR4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugalcdep.2016.11.032","volume":"171","author":"Z Bi-Mohammed","year":"2017","unstructured":"Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122\u201331.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"12685_CR5","first-page":"355","volume":"7","author":"N Cope","year":"2000","unstructured":"Cope N. Drug use in prison: the experience of young offenders. Drugs. 2000;7(4):355\u201366.","journal-title":"Drugs"},{"issue":"4","key":"12685_CR6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/1043986216672770","volume":"32","author":"DP Connor","year":"2016","unstructured":"Connor DP, Tewksbury R. Inmates and prison involvement with drugs: examining drug-related misconduct during incarceration. J Contemp Crim Justice. 2016;32(4):426\u201345.","journal-title":"J Contemp Crim Justice"},{"key":"12685_CR7","first-page":"17","volume-title":"Drug use in prisoners: epidemiology, implications, and policy responses","author":"C Carpentier","year":"2018","unstructured":"Carpentier C, Royuela L, Montanari L, Davis P. The global epidemiology of drug use in prison. In:  Drug use in prisoners: epidemiology, implications, and policy responses. New York: Oxford University Press; 2018. p. 17\u201341."},{"key":"12685_CR8","volume-title":"Substance abuse problem severity, treatment readiness, and response bias among incarcerated men","author":"M Ternes","year":"2014","unstructured":"Ternes M, Johnson S. Substance abuse problem severity, treatment readiness, and response bias among incarcerated men. Ottawa: Correctional Service Canada; 2014. Retrieved from:http:\/\/www.csc-scc.gc.ca\/005\/008\/092\/rs13-05-eng.pdf"},{"key":"12685_CR9","volume-title":"Substance use on day of offence in a sample of male federal offenders","author":"P Mullins","year":"2013","unstructured":"Mullins P, Ternes M, Farrell MacDonald S. Substance use on day of offence in a sample of male federal offenders. Ottawa: Correctional Service Canada; 2013. Retrieved from:http:\/\/www.csc-scc.gc.ca\/research\/005008-rs13-01-eng.shtml"},{"key":"12685_CR10","volume-title":"Substance use patterns of men offenders: an ethnocultural comparison","author":"S Garrel","year":"2019","unstructured":"Garrel S, Farrell MacDonald S. Substance use patterns of men offenders: an ethnocultural comparison. Ottawa: Correctional Service Canada; 2019. Retrieved from:https:\/\/www.csc-scc.gc.ca\/research\/rib-20-04-en.shtml"},{"issue":"4","key":"12685_CR11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000357942","volume":"20","author":"S Farrell MacDonald","year":"2014","unstructured":"Farrell MacDonald S, MacSwain M-A, Cheverie M, Tiesmaki M, Fischer B. Impact of methadone maintenance treatment on women offenders\u2019 post-release recidivism. Eur Addict Res. 2014;20(4):192\u20139.","journal-title":"Eur Addict Res"},{"key":"12685_CR12","volume-title":"Proposed standards for race-based and Indigenous identity and data collection and health reporting in Canada","author":"Canadian Institutes for Health Information (CIHI)","year":"2020","unstructured":"Canadian Institutes for Health Information (CIHI). Proposed standards for race-based and Indigenous identity and data collection and health reporting in Canada: Toronto, Ontario Canadian Institutes for Health Information (CIHI); 2020. Retrieved from:https:\/\/www.cihi.ca\/sites\/default\/files\/document\/proposed-standard-for-race-based-data-en.pdf"},{"key":"12685_CR13","volume-title":"Women offenders, substance use, and behavior","author":"S Farrell MacDonald","year":"2016","unstructured":"Farrell MacDonald S, Gobeil R, Biro SM, Ritchie MB, Curno J. Women offenders, substance use, and behavior. Ottawa: Correctional Service Canada; 2016. Retrieved from:https:\/\/www.csc-scc.gc.ca\/research\/005008-r358-eng.shtml"},{"key":"12685_CR14","volume-title":"Comparing substance use patterns of aboriginal and Non-aboriginal women offenders","author":"S Farrell MacDonald","year":"2014","unstructured":"Farrell MacDonald S. Comparing substance use patterns of aboriginal and Non-aboriginal women offenders. Ottawa: Correctional Service Canada; 2014. Retrieved from:https:\/\/www.csc-scc.gc.ca\/005\/008\/092\/rs14-26-eng.pdf"},{"key":"12685_CR15","volume-title":"Comparison of women offenders who use opioids versus other types of substances","author":"S Cram","year":"2019","unstructured":"Cram S, Farrell-Macdonald S. Comparison of women offenders who use opioids versus other types of substances. Ottawa: Correctional Service Canada; 2019. Retrieved from:https:\/\/www.csc-scc.gc.ca\/005\/008\/092\/rib-19-09-en.pdf"},{"issue":"3","key":"12685_CR16","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.17269\/cjph.105.4193","volume":"105","author":"F Kouyoumdjian","year":"2014","unstructured":"Kouyoumdjian F, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Can J Public Health. 2014;105(3):e198\u2013202.","journal-title":"Can J Public Health"},{"issue":"1\u20132","key":"12685_CR17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2011.12.014","volume":"124","author":"S Johnson","year":"2012","unstructured":"Johnson S, Farrell MacDonald S, Cheverie M, Myrick C, Fischer B. Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. Drug Alcohol Depend. 2012;124(1\u20132):172\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"12685_CR18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/0093854813501495","volume":"41","author":"MA MacSwain","year":"2014","unstructured":"MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (mmt) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2014;41(3):380\u201394.","journal-title":"Crim Justice Behav"},{"key":"12685_CR19","unstructured":"McKendy L, Biro S, Keown LA: Overdose Incidents in cederal Custody, 2012\/2013\u20132016\/2017. 2018. Ottawa, Ontario Correctional Service Canada. Retrieved from:https:\/\/www.csc-scc.gc.ca\/research\/092\/sr-18-02-en.pdf"},{"key":"12685_CR20","volume-title":"Guidance on opioid agoinst treatment (OAT)","author":"Correctional Service Canada","year":"2020","unstructured":"Correctional Service Canada. Guidance on opioid agoinst treatment (OAT). Ottawa: Correctional Service Canada; 2020. Retrieved from:https:\/\/www.csc-scc.gc.ca\/health\/002006-3004-en.shtml?wbdisable=true"},{"issue":"9","key":"12685_CR21","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M-\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247\u201357.","journal-title":"Can Med Assoc J"},{"issue":"11","key":"12685_CR22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","volume":"10","author":"AL Stotts","year":"2009","unstructured":"Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727\u201340.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"12685_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.","journal-title":"Nat Rev Dis Primers"},{"key":"12685_CR24","volume-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people: John Wiley & Sons, Ltd; 2016. Retrieved from:http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD011117.pub2\/abstract"},{"issue":"9","key":"12685_CR25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"12685_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17449200601069676","volume":"2","author":"R Lines","year":"2006","unstructured":"Lines R. From equivalence of standards to equivalence of objectives: the entitlement of prisoners to health care standards higher than those outside prisons. Int J Prison Health. 2006;2(4):269\u201380.","journal-title":"Int J Prison Health"},{"issue":"2","key":"12685_CR27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/08897077.2019.1695706","volume":"41","author":"ER Brezel","year":"2020","unstructured":"Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus. 2020;41(2):150\u20134.","journal-title":"Subst Abus"},{"key":"12685_CR28","volume-title":"The United Nations standard minimum rules for the treatment of prisoners (The Nelson Mandela Rules)","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2015","unstructured":"United Nations Office on Drugs and Crime (UNODC). The United Nations standard minimum rules for the treatment of prisoners (The Nelson Mandela Rules). Vienna: United Nations Office on Drugs and Crime (UNODC); 2015. Retrieved from:https:\/\/www.unodc.org\/documents\/justice-and-prison-reform\/GA-RESOLUTION\/E_ebook.pdf"},{"issue":"2","key":"12685_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1078345819837909","volume":"25","author":"G Sander","year":"2019","unstructured":"Sander G, Shirley-Beavan S, Stone K. The global state of harm reduction in prisons. J Correct Health Care. 2019;25(2):105\u201320.","journal-title":"J Correct Health Care"},{"issue":"2","key":"12685_CR30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1073110518782933","volume":"46","author":"C Bone","year":"2018","unstructured":"Bone C, Eysenbach L, Bell K, Barry DT. Our ethical obligation to treat opioid use disorder in prisons: a patient and physician's perspective. J Law Med Ethics. 2018;46(2):268\u201371.","journal-title":"J Law Med Ethics"},{"key":"12685_CR31","doi-asserted-by":"crossref","first-page":"102768","DOI":"10.1016\/j.drugpo.2020.102768","volume":"81","author":"CE Grella","year":"2020","unstructured":"Grella CE, Ostile E, Scott CK, Dennis M, Carnavale J. A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"12685_CR32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1360-0443.2011.03676.x","volume":"107","author":"D Hedrich","year":"2012","unstructured":"Hedrich D, Alves P, Farrell M, St\u00f6ver H, M\u00f8ller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501\u201317.","journal-title":"Addiction"},{"issue":"2","key":"12685_CR33","doi-asserted-by":"crossref","first-page":"e0192431","DOI":"10.1371\/journal.pone.0192431","volume":"13","author":"FG Kouyoumdjian","year":"2018","unstructured":"Kouyoumdjian FG, Patel A, To MJ, Kiefer L, Regenstreif L. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: a survey. PLoS One. 2018;13(2):e0192431.","journal-title":"PLoS One"},{"key":"12685_CR34","volume-title":"At Rikers Island, a legacy of medication-assisted opioid treatment","author":"C Vestal","year":"2016","unstructured":"Vestal C. At Rikers Island, a legacy of medication-assisted opioid treatment. New York: The PEW Charitable Trusts; 2016. Retrieved from:https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/blogs\/stateline\/2016\/05\/23\/at-rikers-island-a-legacy-of-medication-assisted-opioid-treatment"},{"key":"12685_CR35","first-page":"27","volume":"7","author":"A Sharma","year":"2016","unstructured":"Sharma A, O\u2019Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abus Rehabil. 2016;7:27\u201340.","journal-title":"Subst Abus Rehabil"},{"issue":"2\/3","key":"12685_CR36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10550887.2015.1059217","volume":"34","author":"SE Wakeman","year":"2015","unstructured":"Wakeman SE, Rich JD. Addiction treatment within U.S. correctional facilities: bridging the gap between current practice and evidence-based care. J Addict Dis. 2015;34(2\/3):220\u20135.","journal-title":"J Addict Dis"},{"key":"12685_CR37","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.drugpo.2020.102978","volume":"87","author":"R Komalasari","year":"2021","unstructured":"Komalasari R, Wilson S, Haw S. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in PRISONS. Int J Drug Policy. 2021;87:102978.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"12685_CR38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1108\/IJPH-08-2016-0039","volume":"13","author":"L Brinkley-Rubinstein","year":"2017","unstructured":"Brinkley-Rubinstein L, Cloud DH, Davis C, Zaller N, Delany-Brumsey A, Pope L, et al. Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings. Int J Prison Health. 2017;13(1):25\u201331.","journal-title":"Int J Prison Health"},{"issue":"7","key":"12685_CR39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444\u201350.","journal-title":"Can J Psychiatry"},{"key":"12685_CR40","volume-title":"Institutional methadone maintenance treatment: Impact on release outcome and institutional behaviour","author":"S Johnson","year":"2001","unstructured":"Johnson S, van de Ven JTC, Grant BA. Institutional methadone maintenance treatment: Impact on release outcome and institutional behaviour. Ottawa: Correctional Service Canada; 2001. Retrieved from:http:\/\/www.csc-scc.gc.ca\/text\/rsrch\/reports\/r119\/r119_e.pdf"},{"key":"12685_CR41","volume-title":"Comparing the mental health treatment and abuse histories of men and women methadone maintenance treatment program (MMTP) participants","author":"MA MacSwain","year":"2012","unstructured":"MacSwain MA, Cheverie M. Comparing the mental health treatment and abuse histories of men and women methadone maintenance treatment program (MMTP) participants. Ottawa: Correctional Service Canada; 2012. Retrieved from:http:\/\/www.csc-scc.gc.ca\/research\/005008-rs12-9-eng.shtml"},{"issue":"3","key":"12685_CR42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/0093854813501495","volume":"41","author":"MA MacSwain","year":"2013","unstructured":"MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (MMT) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2013;41(3):380\u201394.","journal-title":"Crim Justice Behav"},{"key":"12685_CR43","volume-title":"CSC Statistics - Key Facts and Figures","author":"Correctional Service Canada","year":"2017","unstructured":"Correctional Service Canada. CSC Statistics - Key Facts and Figures. Ottawa: Government of Canada; 2017. Retrieved from:http:\/\/www.csc-scc.gc.ca\/publications\/005007-3024-eng.shtml"},{"issue":"3","key":"12685_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/02024458-201512000-00002","volume":"6","author":"LO Lanoie","year":"2015","unstructured":"Lanoie LO. Opioid substitution therapy in Canada's prisons. Can J Addict. 2015;6(3):5\u20137.","journal-title":"Can J Addict"},{"key":"12685_CR45","volume-title":"Opioids","author":"Correctional Service Canada","year":"2019","unstructured":"Correctional Service Canada. Opioids. Ottawa: Correctional Service Canada; 2019. Retrieved from:https:\/\/mail.google.com\/mail\/ca\/u\/0\/#inbox"},{"key":"12685_CR46","volume-title":"Opioid Agonist Treatment","author":"Correctional Service Canada","year":"2021","unstructured":"Correctional Service Canada. Opioid Agonist Treatment. Ottawa: Correctional Service Canada; 2021. Retrieved from:https:\/\/www.csc-scc.gc.ca\/health\/002006-3000-en.shtml"},{"key":"12685_CR47","doi-asserted-by":"crossref","unstructured":"Perry AE, Neilson M, James M-S, Glanville JM, Woodhouse R, Godfrey C, et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev. 2015;6:CD010862.","DOI":"10.1002\/14651858.CD010862.pub2"},{"issue":"12","key":"12685_CR48","doi-asserted-by":"crossref","first-page":"e1003002","DOI":"10.1371\/journal.pmed.1003002","volume":"16","author":"M Malta","year":"2019","unstructured":"Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.","journal-title":"PLoS Med"},{"key":"12685_CR49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2018.12.003","volume":"99","author":"KE Moore","year":"2019","unstructured":"Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abus Treat. 2019;99:32\u201343.","journal-title":"J Subst Abus Treat"},{"issue":"4","key":"12685_CR50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"75","author":"TC Green","year":"2018","unstructured":"Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, Boss R, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405\u20137.","journal-title":"JAMA Psychiatry"},{"key":"12685_CR51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2018.09.003","volume":"193","author":"N Bozinoff","year":"2018","unstructured":"Bozinoff N, DeBeck K, Milloy MJ, Nosova E, Fairbairn N, Wood E, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug Alcohol Depend. 2018;193:42\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"12685_CR52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/add.14059","volume":"113","author":"A Russolillo","year":"2018","unstructured":"Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113(4):656\u201367.","journal-title":"Addiction"},{"key":"12685_CR53","volume-title":"Evaluation Report: CSC's Health Services","author":"Correctional Service Canada","year":"2017","unstructured":"Correctional Service Canada. Evaluation Report: CSC's Health Services. Ottawa: Correctional Service Canada (CSC); 2017. Retrieved from:https:\/\/www.csc-scc.gc.ca\/publications\/092\/005007-2017-eng.pdf"},{"issue":"4","key":"12685_CR54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5055\/jom.2009.0024","volume":"5","author":"M McKenzie","year":"2009","unstructured":"McKenzie M, Nunn A, Zaller ND, Bazazi AR, Rich JD. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2009;5(4):219\u201327.","journal-title":"J Opioid Manag"},{"issue":"1\u20132","key":"12685_CR55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","volume":"105","author":"A Nunn","year":"2009","unstructured":"Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1\u20132):83\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"12685_CR56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jurban\/jth147","volume":"81","author":"K Fiscella","year":"2004","unstructured":"Fiscella K, Moore A, Engerman J, Meldrum S. Jail management of arrestees\/inmates enrolled in community methadone maintenance programs. J Urban Health. 2004;81(4):645.","journal-title":"J Urban Health"},{"issue":"4","key":"12685_CR57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijlp.2011.07.002","volume":"34","author":"IA Binswanger","year":"2011","unstructured":"Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. \u201cFrom the prison door right to the sidewalk, everything went downhill,\u201d a qualitative study of the health experiences of recently released inmates. Int J Law Psychiatry. 2011;34(4):249\u201355.","journal-title":"Int J Law Psychiatry"},{"issue":"2","key":"12685_CR58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000199046","volume":"15","author":"S Larney","year":"2009","unstructured":"Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res. 2009;15(2):107\u201312.","journal-title":"Eur Addict Res"},{"key":"12685_CR59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addbeh.2018.02.024","volume":"86","author":"L Brinkley-Rubinstein","year":"2018","unstructured":"Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, et al. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018;86:104\u201310.","journal-title":"Addict Behav."},{"key":"12685_CR60","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.","DOI":"10.1136\/bmj.j1550"},{"key":"12685_CR61","volume-title":"Commissioner's Directives 009 Research","author":"Correctional Service Canada","year":"2017","unstructured":"Correctional Service Canada. Commissioner's Directives 009 Research. Ottawa: Correctional Service Canada; 2017. Retrieved from:https:\/\/www.csc-scc.gc.ca\/lois-et-reglements\/009-cd-en.shtml"},{"key":"12685_CR62","volume-title":"The Offender Management System","author":"Correctional Service Canada","year":"2013","unstructured":"Correctional Service Canada. The Offender Management System. Ottawa: Correctional Service Canada; 2013. Retrieved from:https:\/\/www.csc-scc.gc.ca\/oms\/004003-0001-eng.shtml"},{"key":"12685_CR63","volume-title":"Commissioner\u2019s Directive 705-6: Correctional planning and criminal profile","author":"Correctional Service Canada","year":"2018","unstructured":"Correctional Service Canada. Commissioner\u2019s Directive 705-6: Correctional planning and criminal profile. Ottawa: Correctional Service Canada; 2018. Retrieved from: https:\/\/www.csc-scc.gc.ca\/acts-and-regulations\/705-6-cd-en.shtml"},{"key":"12685_CR64","volume-title":"Development and validation of a criminal risk index (CRI) for federally sentenced offenders in Canada","author":"L Motiuk","year":"2018","unstructured":"Motiuk L, Vuong B. Development and validation of a criminal risk index (CRI) for federally sentenced offenders in Canada. Ottawa: Correctional Service of Canada; 2018. Retrieved from: https:\/\/www.csc-scc.gc.ca\/research\/r-403-en.shtml"},{"key":"12685_CR65","volume-title":"The computerized assessment of substance abuse (CASA): Results from the demonstration project","author":"D Kunic","year":"2006","unstructured":"Kunic D, Grant BA. The computerized assessment of substance abuse (CASA): Results from the demonstration project. Ottawa: Correctional Service Canada; 2006. Retrieved from:https:\/\/www.csc-scc.gc.ca\/research\/r173-eng.shtml"},{"key":"12685_CR66","volume-title":"Research design: qualitative, quantitative, and mixed methods approaches","author":"JW Creswell","year":"2017","unstructured":"Creswell JW, Creswell JD. Research design: qualitative, quantitative, and mixed methods approaches: Sage publications; 2017."},{"issue":"1","key":"12685_CR67","first-page":"45","volume":"15","author":"M Williams","year":"2019","unstructured":"Williams M, Moser T. The art of coding and thematic exploration in qualitative research. Int Manag Rev. 2019;15(1):45\u201355.","journal-title":"Int Manag Rev"},{"key":"12685_CR68","doi-asserted-by":"crossref","first-page":"160940691989922","DOI":"10.1177\/1609406919899220","volume":"19","author":"C O\u2019Connor","year":"2020","unstructured":"O\u2019Connor C, Joffe H. Intercoder reliability in qualitative research: debates and practical guidelines. Int J Qual Methods. 2020;19:1609406919899220.","journal-title":"Int J Qual Methods"},{"issue":"4","key":"12685_CR69","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907.","journal-title":"Qual Quant"},{"issue":"9","key":"12685_CR70","first-page":"14008","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):14008.","journal-title":"Qual Rep"},{"issue":"9","key":"12685_CR71","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S2215-0366(16)30142-0","volume":"3","author":"S Fazel","year":"2016","unstructured":"Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871\u201381.","journal-title":"Lancet Psychiatry"},{"key":"12685_CR72","volume-title":"Spotlight on Gladue: challenges, experiences, and possibilities in Canada's criminal justice system","author":"Department of Justice Canada","year":"2019","unstructured":"Department of Justice Canada. Spotlight on Gladue: challenges, experiences, and possibilities in Canada's criminal justice system. Ottawa: Government of Canada; 2019. Retrieved from:https:\/\/www.justice.gc.ca\/eng\/rp-pr\/jr\/gladue\/p2.html"},{"key":"12685_CR73","first-page":"87","volume":"200","author":"S Boyd","year":"2019","unstructured":"Boyd S, MacPherson D. Vancouver area network of drug users: community engagement - the harms of drug prohibition: ongoing resistance in Vancouver\u2019s downtown eastside. BC Stud. 2019;200:87\u201396.","journal-title":"BC Stud"},{"issue":"3","key":"12685_CR74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/01442879908423778","volume":"20","author":"B Fischer","year":"1999","unstructured":"Fischer B. Prohibition, public health and a window of opportunity: an analysis of Canadian drug policy, 1985-1997. Policy Stud. 1999;20(3):197\u2013210.","journal-title":"Policy Stud"},{"key":"12685_CR75","doi-asserted-by":"crossref","unstructured":"Monico L, Gryczynski J, Lee JD, Dusek K, McDonald R, Malone M, et al. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. J Subst Abus Treat. 2020;108267.","DOI":"10.1016\/j.jsat.2020.108267"},{"key":"12685_CR76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugpo.2019.05.018","volume":"71","author":"SM Bucerius","year":"2019","unstructured":"Bucerius SM, Haggerty KD. Fentanyl behind bars: the implications of synthetic opiates for prisoners and correctional officers. Int J Drug Policy. 2019;71:133\u20138.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"12685_CR77","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/10826084.2016.1264974","volume":"52","author":"E van der Meulen","year":"2017","unstructured":"van der Meulen E. \u201cIt goes on everywhere\u201d: injection drug use in Canadian federal prisons. Subst Use Misuse. 2017;52(7):884\u201391.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"12685_CR78","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1108\/IJPH-04-2016-0009","volume":"12","author":"R Ahmed","year":"2016","unstructured":"Ahmed R, Angel C, Martel R, Pyne D, Keenan L. Access to healthcare services during incarceration among female inmates. Int J Prison Health. 2016;12(4):204\u201315.","journal-title":"Int J Prison Health"},{"issue":"554","key":"12685_CR79","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3399\/bjgp08X330771","volume":"58","author":"E Plugge","year":"2008","unstructured":"Plugge E, Douglas N, Fitzpatrick R. Patients, prisoners, or people? Women prisoners\u2019 experiences of primary care in prison: a qualitative study. Br J Gen Pract. 2008;58(554):e1\u20138.","journal-title":"Br J Gen Pract"},{"issue":"9","key":"12685_CR80","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamainternmed.2018.3504","volume":"178","author":"K Fiscella","year":"2018","unstructured":"Fiscella K, Wakeman SE, Beletsky L. Implementing opioid agonist treatment in correctional facilities. JAMA Intern Med. 2018;178(9):1153\u20134.","journal-title":"JAMA Intern Med"},{"key":"12685_CR81","volume-title":"West Coast Prison Justice Society files human rights complaint against Correctional Service Canada on behalf of federal prisoners with opioid use disorder","author":"West Coast Prison Justice Society","year":"2018","unstructured":"West Coast Prison Justice Society. West Coast Prison Justice Society files human rights complaint against Correctional Service Canada on behalf of federal prisoners with opioid use disorder. Vancouver: West Coast Prison Justice Society (WCPJS); 2018. Retrieved from:https:\/\/prisonjustice.org\/wp-content\/uploads\/2018\/12\/OST-rep-complaint-to-CHRC-20180604-narrative-1.pdf"},{"key":"12685_CR82","volume-title":"Methadone maintenance treatment: Program standards and clinical guidelines","author":"The College of Physicians and Surgeons of Ontario","year":"2011","unstructured":"The College of Physicians and Surgeons of Ontario. Methadone maintenance treatment: Program standards and clinical guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2011. Retrieved from:http:\/\/www.cpso.on.ca\/uploadedFiles\/members\/MMT-Guidelines.pdf"},{"issue":"3","key":"12685_CR83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2105\/AJPH.2018.304852","volume":"109","author":"J Csete","year":"2019","unstructured":"Csete J. Criminal justice barriers to treatment of opioid use disorders in the United States: the need for public health advocacy. Am J Public Health. 2019;109(3):419\u201322.","journal-title":"Am J Public Health"},{"issue":"5","key":"12685_CR84","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2468-2667(18)30078-1","volume":"3","author":"The Lancet Public H","year":"2018","unstructured":"The Lancet Public H. A public health approach to Canada's opioid crisis. Lancet Public Health. 2018;3(5):e204.","journal-title":"Lancet Public Health"},{"issue":"3","key":"12685_CR85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1521-0391.2012.12004.x","volume":"22","author":"J Gryczynski","year":"2013","unstructured":"Gryczynski J, Jaffe JH, Schwartz RP, Du\u0161ek KA, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285\u201391.","journal-title":"Am J Addict"},{"issue":"5","key":"12685_CR86","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02791072.2014.921743","volume":"46","author":"C Teruya","year":"2014","unstructured":"Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46(5):412\u201326.","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"12685_CR87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","volume":"17","author":"RP Schwartz","year":"2008","unstructured":"Schwartz RP, Kelly SM, O'Grady KE, Mitchell SG, Peterson JA, Reisinger HS, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17(5):396\u2013401.","journal-title":"Am J Addict"},{"issue":"1","key":"12685_CR88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","volume":"10","author":"AD Fox","year":"2015","unstructured":"Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"12685_CR89","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13722-019-0166-0","volume":"14","author":"M Velasquez","year":"2019","unstructured":"Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"12685_CR90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-016-3799-7","volume":"32","author":"SE Wakeman","year":"2017","unstructured":"Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17\u20139.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"12685_CR91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330\u20133.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"12685_CR92","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/08897077.2019.1671940","volume":"41","author":"EL Davis","year":"2020","unstructured":"Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: a systematic literature review. Subst Abus. 2020;41(2):216\u201331.","journal-title":"Subst Abus"},{"issue":"1","key":"12685_CR93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"12685_CR94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"12685_CR95","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.pec.2016.12.001","volume":"100","author":"J Trujols","year":"2017","unstructured":"Trujols J, Gonz\u00e1lez-Saiz F, Manresa MJ, Alcaraz S, Batlle F, Duran-Sindreu S, et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 2017;100(5):981\u20136.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"12685_CR96","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1753-6405.2008.00172.x","volume":"32","author":"S Larney","year":"2008","unstructured":"Larney S, Dolan K. Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Aust N Z J Public Health. 2008;32(1):86\u20137.","journal-title":"Aust N Z J Public Health"},{"key":"12685_CR97","doi-asserted-by":"crossref","unstructured":"Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abus Treat. 2021;128;108389.","DOI":"10.1016\/j.jsat.2021.108389"},{"issue":"9","key":"12685_CR98","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17425247.2019.1649252","volume":"16","author":"F Vorspan","year":"2019","unstructured":"Vorspan F, Hjelmstr\u00f6m P, Simon N, Benyamina A, Dervaux A, Brousse G, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal\u00ae in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907\u201314.","journal-title":"Expert Opin Drug Deliv"},{"key":"12685_CR99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cct.2019.02.009","volume":"79","author":"MS Gordon","year":"2019","unstructured":"Gordon MS, Vocci FJ, Taxman F, Fishman M, Sharma B, Blue TR, et al. A randomized controlled trial of buprenorphine for probationers and parolees: bridging the gap into treatment. Contemp Clin Trials. 2019;79:21\u20137.","journal-title":"Contemp Clin Trials"},{"key":"12685_CR100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2016.12.015","volume":"53","author":"MS Gordon","year":"2017","unstructured":"Gordon MS, Vocci FJ, Fitzgerald TT, O'Grady KE, O'Brien CP. Extended-release naltrexone for pre-release prisoners: a randomized trial of medical mobile treatment. Contemp Clin Trials. 2017;53:130\u20136.","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"12685_CR101","first-page":"321","volume":"65","author":"C Korownyk","year":"2019","unstructured":"Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Can Fam Physician. 2019;65(5):321\u201330.","journal-title":"Can Fam Physician"},{"issue":"8","key":"12685_CR102","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/add.14946","volume":"115","author":"A Bahji","year":"2020","unstructured":"Bahji A, Carlone D, Altomare J. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction. 2020;115(8):1413\u201325.","journal-title":"Addiction"},{"issue":"5","key":"12685_CR103","doi-asserted-by":"crossref","first-page":"e0251840","DOI":"10.1371\/journal.pone.0251840","volume":"16","author":"EJ Tian","year":"2021","unstructured":"Tian EJ, Venugopalan S, Kumar S, Beard M. The impacts of and outcomes from telehealth delivered in prisons: a systematic review. Plos One. 2021;16(5):e0251840.","journal-title":"Plos One"},{"issue":"6","key":"12685_CR104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/1357633X19869131","volume":"27","author":"C Edge","year":"2019","unstructured":"Edge C, Black G, King E, George J, Patel S, Hayward A. Improving care quality with prison telemedicine: the effects of context and multiplicity on successful implementation and use. J Telemed Telecare. 2019;27(6):325\u201342.","journal-title":"J Telemed Telecare"},{"key":"12685_CR105","unstructured":"Government of Canada: Opioid- and stimulant-related harms in Canada. 2020. Ottawa: Government of Canada. Retrieved from:https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids\/maps?index=1"},{"issue":"Supplement_5","key":"12685_CR106","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1093\/infdis\/jiaa001","volume":"222","author":"M Krsak","year":"2020","unstructured":"Krsak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid use and chronic infections: The value of addressing the syndemic in correctional settings via telemedicine: Guidance and broader use of long-acting medications. J Infect Dis. 2020;222(Supplement_5):S486\u201393.","journal-title":"J Infect Dis"},{"issue":"1","key":"12685_CR107","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-criminol-061020-125715","volume":"4","author":"JP Caulkins","year":"2021","unstructured":"Caulkins JP, Gould A, Pardo B, Reuter P, Stein BD. Opioids and the criminal justice system: new challenges posed by the modern opioid epidemic. Annu Rev Crim. 2021;4(1):353\u201375.","journal-title":"Annu Rev Crim"},{"key":"12685_CR108","doi-asserted-by":"crossref","unstructured":"Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, et al. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. J Subst Abus Treat. 2020;108241.","DOI":"10.1016\/j.jsat.2020.108241"},{"key":"12685_CR109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsat.2015.07.005","volume":"59","author":"MS Gordon","year":"2015","unstructured":"Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B. A phase 4, pilot, open-label study of VIVITROL\u00ae(extended-release naltrexone XR-NTX) for prisoners. J Subst Abus Treat. 2015;59:52\u20138.","journal-title":"J Subst Abus Treat"},{"key":"12685_CR110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2015.10.023","volume":"157","author":"SA Springer","year":"2015","unstructured":"Springer SA, Altice FL, Brown S-E, Di Paola A. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158\u201365.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"12685_CR111","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09540261.2018.1524373","volume":"30","author":"RP Schwartz","year":"2018","unstructured":"Schwartz RP, Mitchell MM, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, et al. Pharmacotherapy for opioid addiction in community corrections. Int Rev Psychiatry. 2018;30(5):117\u201335.","journal-title":"Int Rev Psychiatry"},{"issue":"6","key":"12685_CR112","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","volume":"110","author":"JD Lee","year":"2015","unstructured":"Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008\u201314.","journal-title":"Addiction"},{"key":"12685_CR113","volume-title":"Opioid agonist treatment","author":"Correctional Service Canada","year":"2019","unstructured":"Correctional Service Canada. Opioid agonist treatment. Ottawa: Correctional Service Canada; 2019. Retrieved from:https:\/\/www.csc-scc.gc.ca\/health\/002006-2007-en.shtml"},{"key":"12685_CR114","volume-title":"Promoting wellness and independence of older persons in CSC custody. A policy framework: Pain Management","author":"Correctional Service Canada","year":"2018","unstructured":"Correctional Service Canada. Promoting wellness and independence of older persons in CSC custody. A policy framework: Pain Management. Ottawa: Correctional Service Canada; 2018. Retrieved from:https:\/\/www.csc-scc.gc.ca\/publications\/005007-1601-en.shtml#6.8"},{"key":"12685_CR115","doi-asserted-by":"crossref","unstructured":"Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(3).","DOI":"10.1186\/1940-0640-7-3"},{"issue":"4","key":"12685_CR116","first-page":"345","volume":"25","author":"J Lee","year":"2016","unstructured":"Lee J, Gordon M, Friedmann P, Nunes E, O'Brien C. Extended-release naltrexone to prevent opioid relapse among adults with criminal justice system involvement. Am J Addict. 2016;25(4):345.","journal-title":"Am J Addict"},{"issue":"2","key":"12685_CR117","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10488-015-0632-2","volume":"43","author":"AL Begun","year":"2016","unstructured":"Begun AL, Early TJ, Hodge A. Mental health and substance abuse service engagement by men and women during community reentry following incarceration. Adm Policy Ment Health Ment Health Serv Res. 2016;43(2):207\u201318.","journal-title":"Adm Policy Ment Health Ment Health Serv Res"},{"key":"12685_CR118","doi-asserted-by":"crossref","first-page":"105766","DOI":"10.1016\/j.ypmed.2019.105766","volume":"128","author":"RA Martin","year":"2019","unstructured":"Martin RA, Gresko SA, Brinkley-Rubinstein L, Stein LAR, Clarke JG. Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Prev Med. 2019;128:105766.","journal-title":"Prev Med"},{"key":"12685_CR119","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","volume":"160","author":"BJH Yarborough","year":"2016","unstructured":"Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"0","key":"12685_CR120","first-page":"073401682098162","volume":"0","author":"SL Canzater","year":"2020","unstructured":"Canzater SL, LaBelle RM. Championing change to save lives: a call to action to implement reforms to increase use of medications to treat opioid use disorder in correctional settings. Crim Justice Rev. 2020;0(0):0734016820981629.","journal-title":"Crim Justice Rev"},{"key":"12685_CR121","volume-title":"Correctional programs","author":"Correctional Service Canada","year":"2019","unstructured":"Correctional Service Canada. Correctional programs. Ottawa: Correctional Service Canada; 2019. Retrieved from:https:\/\/www.csc-scc.gc.ca\/002\/002-0001-en.shtml"},{"key":"12685_CR122","unstructured":"Macmadu A, Rich JD. Correctional health is community health. Issues Sci Technol. 2015;32(1)."},{"key":"12685_CR123","volume-title":"Treating substance use and mental health disorders in correctional settings","author":"L Beletsky","year":"2019","unstructured":"Beletsky L. Treating substance use and mental health disorders in correctional settings: Northeastern Univeristy of Law; 2019. Retrieved from:https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3499366"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-12685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T16:05:25Z","timestamp":1646409925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-12685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12685"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-12685-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all procedures were approved by the Centre for Addiction and Mental Health (CAMH) Research Ethics Board (REB: #013\u20132018). Written informed consent was obtained from all subjects and all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}